We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Bayer Aktiengesellschaft (PK) | USOTC:BAYRY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 7.60 | 7.59 | 7.68 | 7.69 | 7.59 | 7.66 | 2,551,609 | 21:30:14 |
From May 2019 to May 2024
By Donato Paolo Mancini
Bayer AG (BAYN.XE) said late Tuesday that it disagrees with the decision taken by a French court to cancel the marketing authorization for Roundup 360, a glyphosate product it inherited after acquiring Monsanto last year.
Bayer pointed to scientific evidence it said proves glyphosate isn't carcinogenic, and said it is currently reviewing the decision and considering its legal options.
Bayer is currently embroiled in a high-stakes legal challenge in the U.S. over whether glyphosate can cause cancer, after it lost a high-profile case last summer. The German chemicals giant claimed an essential victory earlier this month when it successfully asked for a procedural change in a pivotal trial on the same issue.
Shares in Bayer have lost 37% in the past 12 months, and closed 0.3% higher Tuesday.
Write to Donato Paolo Mancini at donatopaolo.mancini@dowjones.com; @donatopmancini
(END) Dow Jones Newswires
January 15, 2019 11:59 ET (16:59 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Bayer Aktiengesellschaft (PK) Chart |
1 Month Bayer Aktiengesellschaft (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
